Given that the concordance rate for tubal occlusion between HyFoSy and HSG was not 100%, an occluded fallopian tube on HyFoSy should be confirmed by HSG, which remains the reference standard for confirmation of tubal occlusion after Essure hysteroscopic sterilization.

Objectives: The aim of the study was to compare associations between blood flow volumes measured by the PixelFlux-Technique with measurements from time-averaged maximum velocity (TAmax). Methods: We conducted a prospective cohort study in 47 women with single pregnancies in week 24. Blood flow volume (ml/minute) in the uterine arteries was first calculated as 0.5*TAmax * cross section area of the vessel (cm 2 ) * 60. CSA was calculated as π * (diameter/2) 2 assuming that the uterine vessels were circular. Thereafter the blood flow was calculated using the PixelFlux method. PixelFlux is a new method based on pixelwise calculation of spatially angle-corrected velocities and areas of all pixels inside a vessel. Velocity is coded by colour, and by comparing the colour of each pixel in the cross-sectional area with the preset colour bar, it is possible to measure blood flow velocities directly. Then, all pixels' flow volumes inside a vessels section are added to calculate the flow volume of the vessel during a heart cycle. Figure 1 illustrates a uterine artery in the systole and the diastole. All the calculations and measurements are done automatically by the PixelFlux program. Results: The mean flow calculated from PixelFlux was 811ml/minute vs. 777ml calculated from TAmax. The mean difference was 24 ml/minute (95% CI -45; 94 ml/minute) and we did not observe any significant difference between the two methods due to the fact that the CI intervals were crossing zero. The intra class correlation coefficient was 0.83 (95% CI 0.72-0.90) and limits of agreement were -441 ml/minute to 489 ml/minute. Conclusions: The PixelFlux method might be an easy and promising tool in calculating blood flow volumes in the uterine arteries directly.Supporting information can be found in the online version of this abstract Objectives: Microcephaly is one of the most common fetal structural abnormalities, and prenatal microcephaly is considered a group I malformation of cortical development diagnosed according to ultrasonographic (US) skull measurements. The purpose of this study is too evaluate the agreement between fetal head US and MRI biometric measurements of suspected microcephalic fetuses. Methods: This institutional review board-approved retrospective study with waived informed consent included 180 pregnant women and was conducted at our medical centre from March 2011 to April 2013. Biparietal and occipitofrontal diameter results of fetal head US normograms were compared to normograms for MRI. We used Pearson and Spearman rho non-parametric correlation coefficients to assess the association between two quantitative variables, paired t-test for paired quantitative variables, and McNemar test for paired qualitative variables. Results: The average biparietal diameter but not the average occipitofrontal diameter percentiles in fetal head US differed significantly from the MRI results (P < 0.0001). When looking at the accepted microcephaly threshold, both biparietal diameter and occipitofrontal diameter percentiles differed significant...

Background The objective of our study was to assess the rate and causes for Essure® micro-insert system removal and patients’ long term satisfaction rate with the procedure. Methods All patients who underwent Essure® hysteroscopic sterilization at our tertiary centre between years 2007 and 2018 were included in this follow-up study. A questionnaire was sent to all patients per standard mail. Patients who did not respond to questionnaires per mail, were called by phone. The satisfaction with the Essure® sterilization, as well as any additional procedures after the insertion or insertion-related complications were analysed. Results From the year 2007 to 2018, we performed 427 Essure® hysteroscopic sterilizations and of these, 329 patients responded to the questionnaire (response rate 77%). Ten patients (3%) had Essure® removal, two of them due to pain (0.6%). Patients were very satisfied with the procedure (9.5 on scale 0–10). Most patients (95.3%) would recommend the procedure to their friend. Conclusions Essure® hysteroscopic sterilization is a procedure with a very high satisfaction rate and a very low removal rate due to sterilization-related complications. Trial registration Institutional review board of University medical centre Maribor approved the study, approval number UKC-MB-KME-73/19.

Background: The objective of our study was to assess the rate and causes for Essure® micro-insert system removal and patients’ long term satisfaction rate with the procedure.Methods: All patients who underwent Essure® hysteroscopic sterilization at our tertiary centre between years 2007 and 2018 were included in this follow-up study. A questionnaire was sent to all patients per standard mail. Patients who did not respond to questionnaires per mail, were called by phone. The satisfaction with the Essure® sterilization, as well as any additional procedures after the insertion or insertion-related complications were analysed. Results: From the year 2007 to 2018, we performed 427 Essure® hysteroscopic sterilizations and of these, 329 patients responded to the questionnaire (response rate 77%). Ten patients (3%) had Essure® removal, two of them due to pain (0.6%). Patients were very satisfied with the procedure (9.5 on scale 0 – 10). Most patients (95.3%) would recommend the procedure to their friend.Conclusions: The rate of the Essure® micro-insert system removal due to sterilization-related complications is very low. Essure® hysteroscopic sterilization is a safe and effective procedure with a very high satisfaction rate.Trial registration: Institutional review board approval was obtained for the study, approval number UKC-MB-KME-73/19.

Objective: We aimed to identify factors that significantly influence the development of thromboembolism during pregnancy and in the postpartum period among factor V Leiden carriers. Methods: A controlled retrospective study was performed on 301 pregnancies of a cohort of 145 FVL-carrier women. Data of individual pregnancies, deliveries, complications including thromboembolism in the index pregnancy and prophylaxis were obtained by structured interview and by review of case-notes. Full-length thrombosis prophylaxis was employed in forty-eight pregnancies. Logistic regression analysis was performed to identify factors that significantly influence the occurrence of deep vein thrombosis or thromboembolism during pregnancy and in the postpartum period. Results: Two-hundred out of the 301 pregnancies ended with childbirth and there were 40 spontaneous abortions. Preterm birth, preeclampsia, placental insufficiency, intrauterine growth retardation, placental abruption, premature rupture of the membranes, uterine inertia, Caesarean section, febrile complication and major haemorrhage occurred in 29, 13, 27, 9, 4, 14, 12, 33, 10 and 7 cases, respectively. Twenty-five pregnancies were complicated by deep vein thrombosis (DVT) or thromboembolism. Thirty-six pregnancies were conceived with past history of deep vein thrombosis and 43 pregnancies were carried in the presence of combined thrombophilia. Prophylaxis alone did not affect the occurrence of pregnancy associated DVT among factor V Leiden carriers (p = 0.2571). Prophylaxis did not affect the occurrence of DVT among women with a history of DVT (p = 0.7199) or among those without a history of DVT (p = 0.1077), however, in the latter group, DVT occurred only when no prophylaxis was given. Pregnancy associated DVT was strongly associated with combined thrombophilia among factor V Leiden carriers (p = 0.0001). Among pregnancies that ended with a Caesarean section (18 without prophylaxis, 15 with prophylaxis) DVT occurred only when no prophylaxis was given (5 cases, p = 0.0267). In a logistic regression model, factors that significantly influenced the development of deep vein thrombosis included gestational age (OR = 1.058, p = 0.0089), the use of thrombosis prophylaxis (OR = 0.118, p = 0.0227) and the presence of combined thrombophilia (OR = 5.835, p = 0.0005). The frequency of premature rupture of the membranes and Caesarean section was significantly higher in those pregnancies in which thrombosis prophylaxis was employed (OR = 7.102, 0.027; OR = 4.129, p = 0.0378, respectively). Conclusion: Thrombosis prophylaxis decreases the risk of pregnancy associated DVT among factor V Leiden carriers. The effect increases with the length of gestation and is significant when combined thrombophilia is present or delivery is affected by Caesarean section. Selective thrombosis prophylaxis among pregnant factor V Leiden carriers might be the presence of combined thrombophilia and Caesarean section.